MannKind Management
Management criteria checks 3/4
MannKind's CEO is Michael Castagna, appointed in May 2017, has a tenure of 9.33 years. total yearly compensation is $9.30M, comprised of 8.5% salary and 91.5% bonuses, including company stock and options. directly owns 0.76% of the company’s shares, worth $8.62M. The average tenure of the management team and the board of directors is 3.3 years and 6.7 years respectively.
Key information
Michael Castagna
Chief executive officer
US$9.3m
Total compensation
| CEO salary percentage | 8.49% |
| CEO tenure | 9.3yrs |
| CEO ownership | 0.8% |
| Management average tenure | 3.3yrs |
| Board average tenure | 6.7yrs |
Recent management updates
Recent updates
Narrative Update • Aug 17
MNKD: Upcoming Autoinjector Decision Will Reframe Perceived Royalty Risk
Analysts have raised their fair value estimate for MannKind from $11.00 to approximately $12.74, citing a higher Street price target of $14 that is tied to Furoscix and MNKD-201 expectations, as well as increased attention on the upcoming Furoscix ReadyFlow Autoinjector FDA decision. Analyst Commentary Recent commentary from bullish analysts on MannKind centers on rising confidence in the Furoscix franchise and the MNKD-201 program.Seeking Alpha • Aug 13
MannKind: New Approvals Majorly Increase MannKind's Prospects
Summary Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promise of turbocharging product growth in two of MNKD's established products. MNKD's existing liquidity should be adequate to fund its operations and launches for ~2.3 years. While I rate MNKD a " Strong Buy" based upon its FDA approvals, it still has significant risks of execution. Read the full article on Seeking AlphaNarrative Update • Aug 03
MNKD: Furoscix Autoinjector Approval Will Reset Perceived Royalty Risk
Analysts have lifted their price target on MannKind to $14 from $11, citing higher expectations for Furoscix and the '201 program, along with updated assumptions around tissue exposure and potential Phase 2 read-throughs. Analyst Commentary Recent research coverage around MannKind highlights growing confidence in the company’s pipeline and product execution, particularly around Furoscix and the '201 program.
Narrative Update • Jun 22
MNKD: Pediatric Insulin Approval Will Test Commercial Execution And Reprice Future Upside
The latest narrative update on MannKind reflects a higher analyst price target, moving from $7.17 to $7.59, as analysts highlight Afrezza's pediatric approval while still viewing the company as a "show me" story on commercial execution. Analyst Commentary Recent research on MannKind centers on how Afrezza's pediatric approval could affect the company's long term commercial story, while mixed target moves show differing views on execution risk and valuation.Narrative Update • Jun 05
MNKD: Pediatric Approval And Trial Progress Will Reset Perceived Royalty Risk
Analysts have raised their MannKind price target to $11 from $8. This reflects updated assumptions that include Afrezza's pediatric approval, a lower discount rate, and higher expected profit margins, even as projected revenue growth and future P/E move slightly lower.
Narrative Update • May 21
MNKD: 2026 Pediatric Decision Will Shape Royalty Overhang And Rebound Potential
Analysts have updated their view on MannKind with a new fair value estimate of $4.75 per share, reflecting recent shifts in price targets as they balance concerns about Tyvaso DPI royalty risk against ongoing contributions from products like Furoscix and Afrezza. Analyst Commentary Recent research highlights a split in how professionals are valuing MannKind, with much of the debate centered on the durability of Tyvaso DPI royalties and how that uncertainty should be reflected in the share price.Narrative Update • May 04
MNKD: Soft Mist Inhaler Risk Seen Resetting Future Royalty Upside
Narrative Update Analysts have trimmed their average price target on MannKind to about $8. This reflects updated assumptions for higher revenue growth but lower profit margins and a more moderate future P/E as they weigh potential long term risks to Tyvaso DPI royalties from United Therapeutics' soft mist inhaler plans.Narrative Update • Apr 20
MNKD: 2026 Pediatric Insulin Decision Will Reset Treprostinil Royalty Risk
Analysts have trimmed MannKind's average price target by about $0.33, reflecting slightly lower assumptions for fair value and profitability as they factor in potential long term risks to Tyvaso DPI royalties from United Therapeutics' soft mist inhaler plans, even though some still see opportunity in the broader portfolio. Analyst Commentary Recent research has become more cautious on MannKind, with several firms trimming price targets and one moving to a more neutral rating as they reassess the risk and reward around Tyvaso DPI royalties and the impact of United Therapeutics' soft mist inhaler plans.Narrative Update • Apr 06
MNKD: 2026 Pediatric Decision Will Define Royalty Overhang And Bullish Setup
Narrative Update: MannKind MannKind's updated analyst price target has been reduced from about $7.50 to roughly $3.85, as analysts factor in softer modeled revenue growth, a higher discount rate, lower assumed future P/E and rising concerns that United Therapeutics' planned soft mist inhaler could weigh on the long term value of Tyvaso DPI royalties. Some still highlight potential support from Afrezza and Furoscix and argue the recent selloff may already reflect a worst case scenario.Narrative Update • Mar 22
MNKD: 2026 Afrezza FDA Decisions Will Recast Treprostinil Royalty Risk
Analysts have trimmed their average price targets on MannKind by a few dollars into the mid single digit range, reflecting fresh concerns about long term Tyvaso DPI royalties as United Therapeutics pursues a soft mist inhaler, while still recognizing potential support from Furoscix and Afrezza. Analyst Commentary Recent Street commentary on MannKind highlights a split view, with many price targets pulled into a mid single digit to low double digit range as analysts weigh Tyvaso DPI royalty risk against potential contributions from Afrezza and Furoscix, as well as MannKind's broader pipeline.Narrative Update • Mar 08
MNKD: 2026 FDA Decisions On Inhaled Insulin Will Reframe Royalty Risk
Analysts have trimmed their fair value view on MannKind to $7.50 from $9.61, citing lower price targets clustered around $3.50 to $11 as they factor in softer revenue growth and profit margin assumptions, as well as higher perceived risk tied to United Therapeutics' potential soft mist inhaler competition and the timing of Tyvaso DPI royalty data. Analyst Commentary Recent Street research on MannKind reflects a wide split in opinion, with some analysts focusing on potential upside from the broader product portfolio and others emphasizing new competitive risks to Tyvaso DPI royalties and collaboration revenue.Narrative Update • Feb 22
MNKD: 2026 FDA Label And Pediatric Decisions Will Drive Bullish Case
Analysts have kept their fair value estimate for MannKind steady while refining key inputs like discount rate, revenue growth, profit margin and future P/E. They link their current price targets, including one at $11, to what they see as multiple potential tailwinds tied to upcoming FDA decisions on Afrezza in 2026.Narrative Update • Feb 07
MNKD: Upcoming FDA Decisions In 2026 Will Define Upside Potential
Narrative Update on MannKind Analysts have trimmed their price target on MannKind from $8.00 to $7.50, balancing reduced fair value and margin assumptions with expectations for stronger revenue growth. They also recognize that recent Street research still highlights potential tailwinds tied to upcoming FDA decisions and the updated pipeline outlook.Narrative Update • Jan 23
MNKD: 2026 FDA Label Decisions Will Clarify Underappreciated Upside Potential
Narrative Update on MannKind The analyst price target for MannKind has been reset to $10, reflecting updated views after one firm removed MNKD-101/NTM from its valuation while others highlight potential upside tied to upcoming FDA decisions and what they see as underappreciated tailwinds into 2026. Analyst Commentary Recent research on MannKind reflects a mix of optimism around upcoming FDA decisions and caution after the removal of MNKD-101/NTM from valuation models.Narrative Update • Jan 09
MNKD: 2026 Regulatory Decisions Will Drive Reassessment Of Future Prospects
Narrative Update: MannKind Analyst Price Target Shift Analysts have reset their price targets on MannKind into a tighter US$10 to US$11 range, reflecting a mix of reduced expectations after the discontinuation of MNKD-101/NTM and continued optimism around potential 2026 tailwinds that are not yet fully reflected in the shares. Analyst Commentary Recent research views on MannKind reflect both optimism around potential 2026 catalysts and caution following pipeline changes and trial outcomes.Narrative Update • Dec 23
MNKD: Future Commercial Execution Will Offset Late Stage Pipeline Disappointment
Analysts have trimmed their price target on MannKind to approximately $10 per share, a modest reduction that reflects the removal of MNKD-101/NTM from valuation assumptions, while improved revenue growth and profit margin forecasts partially offset the impact. Analyst Commentary Analyst reactions to the updated price target highlight a mixed outlook, with optimism around MannKind's core commercial performance tempered by concern over the setback in its development pipeline.Narrative Update • Dec 09
MNKD: Future Commercial Portfolio Will Offset Pipeline Setback Risk
Analysts have reduced their price target on MannKind from $15.00 to $10.00 per share, citing the removal of MNKD-101/NTM from the pipeline following the discontinuation of the Phase 3 ICoN-1 trial after a futility assessment. Analyst Commentary Analysts view the updated price target as a recalibration of MannKind's valuation to reflect the loss of MNKD-101/NTM from the development pipeline, while still recognizing ongoing strengths in the core business and broader platform.Narrative Update • Nov 25
MNKD: Recent Pipeline Setback Will Be Outweighed By Future Royalties Expansion
Analysts have reduced their price target for MannKind from approximately $10.06 to $9.39, citing the discontinued Phase 3 ICoN-1 trial and adjusted pipeline expectations as the main factors for the revision. Analyst Commentary Analyst sentiment on MannKind has shifted in response to recent clinical trial results, pipeline updates, and royalty projections.Narrative Update • Nov 11
MNKD: Acquisition Will Drive Revenue Diversification and Support Upside Re-Rating
MannKind's fair value estimate has been revised down slightly to $10.06 per share from $10.57. Analysts are factoring in stronger revenue growth driven by TYVASO DPI royalties and the accretive acquisition of scPharmaceuticals, along with a modest change in profitability and updated discount rates.Analysis Article • Sep 03
MannKind Corporation (NASDAQ:MNKD) Looks Just Right With A 53% Price Jump
MannKind Corporation ( NASDAQ:MNKD ) shareholders would be excited to see that the share price has had a great month...Narrative Update • Aug 27
Pipeline Advancements And International Expansion Will Shape Future Markets
Analysts have raised MannKind’s price target to $9.71, citing the accretive acquisition of scPharmaceuticals, which expands and diversifies MannKind’s addressable market and growth prospects despite recent negative sentiment around earnings. Analyst Commentary Bullish analysts see the acquisition of scPharmaceuticals as adding a high-growth, large-market asset that diversifies MannKind's revenue base.Analysis Article • May 11
Earnings Miss: MannKind Corporation Missed EPS By 5.9% And Analysts Are Revising Their Forecasts
Shareholders might have noticed that MannKind Corporation ( NASDAQ:MNKD ) filed its first-quarter result this time last...Analysis Article • Mar 01
MannKind Corporation Just Missed EPS By 6.3%: Here's What Analysts Think Will Happen Next
MannKind Corporation ( NASDAQ:MNKD ) shareholders are probably feeling a little disappointed, since its shares fell...Seeking Alpha • Dec 17
MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets
Summary MannKind Corporation is a biopharmaceutical company focused on inhaled therapies for endocrine and orphan lung diseases. MNKD's revenue growth is driven by Tyvaso DPI royalties and Afrezza expansion, with pediatric trials targeting a significant underserved market. MNKD's pipeline includes MNKD-101 for nontuberculous mycobacterial lung disease and MNKD-201 for idiopathic pulmonary fibrosis, with significant market potential if successfully commercialized. The orphan lung pipeline includes MNKD-101 (Phase 3 for NTM lung disease) and MNKD-201 (Phase 1 for IPF), addressing high unmet needs. Despite high leverage, I believe MNKD's revenue growth prospects support a speculative "Buy" rating for investors seeking exposure to IPF and endocrine biotech niches. Read the full article on Seeking AlphaSeeking Alpha • Oct 03
MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion
Summary MannKind's stock has surged 73%, driven by its 9% royalty stake in United Therapeutics' Tyvaso DPI, which excels in the PAH market. In Q2 2024, MannKind's revenues rose 49% year-over-year to $72 million, largely due to Tyvaso DPI royalties and manufacturing income. MannKind is advancing a promising pipeline, including MNKD 101 and Nintedanib DPI, aimed at addressing unmet needs in orphan lung diseases. Financially, MannKind has strong liquidity but remains burdened by long-term debt obligations and modest net losses. I maintain a "buy" recommendation based on MannKind's solid revenue from Tyvaso DPI and its potential in expanding respiratory treatments. Read the full article on Seeking AlphaAnalysis Article • Sep 18
MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Despite an already strong run, MannKind Corporation ( NASDAQ:MNKD ) shares have been powering on, with a gain of 28% in...
New Narrative • Sep 12
Innovative Pipeline And Decisive Deleveraging Poise Company For Explosive Growth And Profitability
Strong demand for Tyvaso DPI and advancements in pipeline drugs like clofazimine inhalation suspension highlight MannKind's successful commercial execution and promising revenue growth prospects.Analysis Article • Jul 17
Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?
Key Insights The projected fair value for MannKind is US$11.86 based on 2 Stage Free Cash Flow to Equity MannKind is...Seeking Alpha • May 15
MannKind Outperforms As Tyvaso DPI Captures Market Share
Summary MannKind's Q1 revenue rose 63% year-over-year; net income was $10.63 million, reversing a prior loss. Tyvaso DPI, utilizing MannKind’s technosphere technology, continues to capture significant PAH market interest. Despite high current assets, the Company's long-term liabilities exceed its assets, posing potential financial risks. Recommend buying MNKD for a barbell strategy portfolio, allocating a small portion to this high-alpha stock. Read the full article on Seeking AlphaCEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$44m |
| Mar 31 2026 | n/a | n/a | -US$24m |
| Dec 31 2025 | US$9m | US$789k | US$6m |
| Sep 30 2025 | n/a | n/a | US$29m |
| Jun 30 2025 | n/a | n/a | US$33m |
| Mar 31 2025 | n/a | n/a | US$30m |
| Dec 31 2024 | US$9m | US$766k | US$28m |
| Sep 30 2024 | n/a | n/a | US$22m |
| Jun 30 2024 | n/a | n/a | US$12m |
| Mar 31 2024 | n/a | n/a | US$8m |
| Dec 31 2023 | US$7m | US$702k | -US$12m |
| Sep 30 2023 | n/a | n/a | -US$31m |
| Jun 30 2023 | n/a | n/a | -US$47m |
| Mar 31 2023 | n/a | n/a | -US$71m |
| Dec 31 2022 | US$4m | US$623k | -US$87m |
| Sep 30 2022 | n/a | n/a | -US$98m |
| Jun 30 2022 | n/a | n/a | -US$88m |
| Mar 31 2022 | n/a | n/a | -US$94m |
| Dec 31 2021 | US$4m | US$598k | -US$81m |
| Sep 30 2021 | n/a | n/a | -US$79m |
| Jun 30 2021 | n/a | n/a | -US$86m |
| Mar 31 2021 | n/a | n/a | -US$61m |
| Dec 31 2020 | US$4m | US$495k | -US$57m |
| Sep 30 2020 | n/a | n/a | -US$45m |
| Jun 30 2020 | n/a | n/a | -US$44m |
| Mar 31 2020 | n/a | n/a | -US$46m |
| Dec 31 2019 | US$2m | US$511k | -US$52m |
Compensation vs Market: Michael's total compensation ($USD9.30M) is above average for companies of similar size in the US market ($USD3.51M).
Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.
CEO
Michael Castagna (50 yo)
9.3yrs
Tenure
US$9,300,485
Compensation
Dr. Michael E. Castagna, Pharm D., has been Chief Executive Officer of MannKind Corporation since May 25, 2017. Dr. Castagna served as Chief Commercial Officer of MannKind Corporation since March 14, 2016...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 9.3yrs | US$9.30m | 0.76% $ 8.6m | |
| Chief Financial Officer | 2.4yrs | US$2.89m | 0.030% $ 339.3k | |
| Executive VP | 24.7yrs | US$3.16m | 0.19% $ 2.2m | |
| Chief People & Workplace Officer | 9.8yrs | US$2.95m | 0.27% $ 3.1m | |
| President of Endocrine Business Unit | 1.7yrs | US$6.99m | 0.015% $ 165.6k | |
| Executive Vice President of Technical Operations | 3.9yrs | US$1.12m | 0.079% $ 897.1k | |
| Executive VP & Chief Medical Officer | 1yr | no data | no data | |
| Senior VP and Therapeutic Area Head of Respiratory & (interim) Cariorenal | 2.7yrs | no data | no data |
3.3yrs
Average Tenure
56yo
Average Age
Experienced Management: MNKD's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 9.3yrs | US$9.30m | 0.76% $ 8.6m | |
| Independent Director | 22.9yrs | US$321.54k | 0.041% $ 468.5k | |
| Chairman Emeritus | 2yrs | US$213.46k | no data | |
| Independent Director | 7.8yrs | US$306.54k | 0.0086% $ 98.0k | |
| Independent Director | 22.8yrs | US$296.54k | 0.0046% $ 52.9k | |
| Independent Director | 6.7yrs | US$319.85k | 0.073% $ 835.9k | |
| Independent Chairman | 11.3yrs | US$349.04k | 0.011% $ 129.1k | |
| Independent Director | 5.8yrs | US$307.35k | 0.033% $ 378.9k | |
| Member of Scientific Advisory Board | 5.1yrs | no data | no data | |
| Independent Director | 1.9yrs | US$291.54k | 0.18% $ 2.1m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.5yrs | US$311.54k | 0.034% $ 391.9k |
6.7yrs
Average Tenure
66.5yo
Average Age
Experienced Board: MNKD's board of directors are considered experienced (6.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/20 06:24 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MannKind Corporation is covered by 27 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Russo | Baird |
| Stephen V. Byrne | BofA Global Research |
| null null | BTIG |